allogeneic iPSC-derived anti-CD19-CAR/IL-15-expressing NK cells CNTY-101
Term · Oncology and biomedicine · MLC-T-ONC-009912
A preparation of allogeneic natural killer (NK) cells derived from a clonal master induced pluripotent stem cell (iPSC) line, and engineered to express a chimeric antigen receptor (CAR) consisting of an anti-CD19 single chain variable fragment (scFv) derived from the anti-CD19 monoclonal antibody FMC63 and coupled to the CD28 and zeta chain of the TCR/CD3 complex (CD3-zeta) costimulatory signaling domains, and interleukin 15 (IL-15), with potential immunostimulatory and antineoplastic activities. Upon administration, allogeneic iPSC-derived anti-CD19-CAR/IL-15-expressing NK cells CNTY-101 recognize, bind to and induce selective cytotoxicity in CD19-expressing tumor cells. IL-15 is a pro-survival cytokine that promotes T-cell persistence and potentiates the immune response against tumor cells. The human tumor associated antigen (TAA) CD19 is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies. CNTY-101 is also engineered with a safety switch composed of a shorter version of the extracellular domain of human epidermal growth factor receptor (EGFR). This allows the elimination of CNTY-101 upon the administration of anti-EGFR antibodies such as cetuximab. In addition, CNTY-101 is gene-edited to prevent its elimination by the patient’s NK cells, CD4 and CD8 T cells.
| Identifier | MLC-T-ONC-009912 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | allogeneic iPSC-derived anti-CD19-CAR/IL-15-expressing natural killer cells CNTY-101; allogeneic iPSC-derived anti-CD19-CAR-CD28-CD3zeta-IL-15-expressing NK cells CNTY-101; allogeneic anti-CD19-CAR-iPSC-derived natural killer cells CNTY-101; allogeneic anti-CD19-CAR-iNK cells CNTY-101 |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-009912",
"term": "allogeneic iPSC-derived anti-CD19-CAR/IL-15-expressing NK cells CNTY-101",
"field": "Oncology and biomedicine",
"definition": "A preparation of allogeneic natural killer (NK) cells derived from a clonal master induced pluripotent stem cell (iPSC) line, and engineered to express a chimeric antigen receptor (CAR) consisting of an anti-CD19 single chain variable fragment (scFv) derived from the anti-CD19 monoclonal antibody FMC63 and coupled to the CD28 and zeta chain of the TCR/CD3 complex (CD3-zeta) costimulatory signaling domains, and interleukin 15 (IL-15), with potential immunostimulatory and antineoplastic activities. Upon administration, allogeneic iPSC-derived anti-CD19-CAR/IL-15-expressing NK cells CNTY-101 recognize, bind to and induce selective cytotoxicity in CD19-expressing tumor cells. IL-15 is a pro-survival cytokine that promotes T-cell persistence and potentiates the immune response against tumor cells. The human tumor associated antigen (TAA) CD19 is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies. CNTY-101 is also engineered with a safety switch composed of a shorter version of the extracellular domain of human epidermal growth factor receptor (EGFR). This allows the elimination of CNTY-101 upon the administration of anti-EGFR antibodies such as cetuximab. In addition, CNTY-101 is gene-edited to prevent its elimination by the patient’s NK cells, CD4 and CD8 T cells.",
"synonyms": [
"allogeneic iPSC-derived anti-CD19-CAR/IL-15-expressing natural killer cells CNTY-101",
"allogeneic iPSC-derived anti-CD19-CAR-CD28-CD3zeta-IL-15-expressing NK cells CNTY-101",
"allogeneic anti-CD19-CAR-iPSC-derived natural killer cells CNTY-101",
"allogeneic anti-CD19-CAR-iNK cells CNTY-101"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/allogeneic-ipsc-derived-anti-cd19-car-il-15-expressing-nk-cells-cnty-101/"
}
Record 798 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.